AR107494A1 - Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma - Google Patents

Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma

Info

Publication number
AR107494A1
AR107494A1 ARP170100246A ARP170100246A AR107494A1 AR 107494 A1 AR107494 A1 AR 107494A1 AR P170100246 A ARP170100246 A AR P170100246A AR P170100246 A ARP170100246 A AR P170100246A AR 107494 A1 AR107494 A1 AR 107494A1
Authority
AR
Argentina
Prior art keywords
azd9291
salt
aniline
preparation
formula
Prior art date
Application number
ARP170100246A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Telford
Alistair John Boyd
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57984913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR107494(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR107494A1 publication Critical patent/AR107494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP170100246A 2016-02-01 2017-01-31 Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma AR107494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662289390P 2016-02-01 2016-02-01

Publications (1)

Publication Number Publication Date
AR107494A1 true AR107494A1 (es) 2018-05-02

Family

ID=57984913

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100246A AR107494A1 (es) 2016-02-01 2017-01-31 Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma

Country Status (18)

Country Link
US (1) US11180477B2 (cg-RX-API-DMAC7.html)
EP (1) EP3411038B1 (cg-RX-API-DMAC7.html)
JP (1) JP6812449B2 (cg-RX-API-DMAC7.html)
KR (1) KR102749892B1 (cg-RX-API-DMAC7.html)
CN (1) CN108495632B (cg-RX-API-DMAC7.html)
AR (1) AR107494A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017214243B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018014712B1 (cg-RX-API-DMAC7.html)
CA (1) CA3011809C (cg-RX-API-DMAC7.html)
CO (1) CO2018007008A2 (cg-RX-API-DMAC7.html)
ES (1) ES2834608T3 (cg-RX-API-DMAC7.html)
IL (1) IL260665B (cg-RX-API-DMAC7.html)
MX (1) MX378363B (cg-RX-API-DMAC7.html)
MY (1) MY185367A (cg-RX-API-DMAC7.html)
RU (1) RU2733376C2 (cg-RX-API-DMAC7.html)
TW (1) TWI745345B (cg-RX-API-DMAC7.html)
WO (1) WO2017134051A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805790B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7030066B2 (ja) 2016-05-26 2022-03-04 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｅｇｆｒ阻害剤化合物
CN107556293B (zh) * 2017-09-19 2019-12-03 福建省微生物研究所 一种奥西替尼的合成工艺
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
CA3229553A1 (en) 2021-09-02 2023-03-09 Synthon B.V. A process for making osimertinib
WO2025124936A1 (en) 2023-12-15 2025-06-19 Synthon B.V. A process for making osimertinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070401A (en) * 1972-02-19 1978-01-24 Mitsui Toatsu Chemicals Inc. Method for the preparation of a halogenated aromatic amine
DK3686194T3 (da) * 2011-07-27 2021-11-22 Astrazeneca Ab 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser
SMT201900142T1 (it) * 2014-06-19 2019-05-10 Ariad Pharma Inc Composti eteroarilici per inibizione di chinasi
CN104817541B (zh) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法

Also Published As

Publication number Publication date
US20210122734A1 (en) 2021-04-29
JP6812449B2 (ja) 2021-01-13
TWI745345B (zh) 2021-11-11
CN108495632A (zh) 2018-09-04
ZA201805790B (en) 2024-10-30
ES2834608T3 (es) 2021-06-18
AU2017214243A1 (en) 2018-09-06
KR20180101610A (ko) 2018-09-12
BR112018014712A2 (pt) 2018-12-11
US11180477B2 (en) 2021-11-23
EP3411038A1 (en) 2018-12-12
TW201736364A (zh) 2017-10-16
CA3011809C (en) 2024-02-27
RU2018130327A3 (cg-RX-API-DMAC7.html) 2020-03-26
IL260665B (en) 2021-08-31
AU2017214243B2 (en) 2019-07-18
KR102749892B1 (ko) 2025-01-07
CN108495632B (zh) 2021-12-31
MY185367A (en) 2021-05-11
JP2019508387A (ja) 2019-03-28
CA3011809A1 (en) 2017-08-10
BR112018014712B1 (pt) 2023-10-31
EP3411038B1 (en) 2020-09-09
MX378363B (es) 2025-03-10
RU2733376C2 (ru) 2020-10-01
WO2017134051A1 (en) 2017-08-10
MX2018008966A (es) 2018-09-03
RU2018130327A (ru) 2020-03-04
CO2018007008A2 (es) 2018-07-19

Similar Documents

Publication Publication Date Title
AR107494A1 (es) Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
AR126445A2 (es) Metodo para preparar inhibidores de btk
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CO6630136A2 (es) Procedimiento para la preparación de 4-{4[({4-cloro-3-(trifluorometil) fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carbocamida, sus sales y su monohidrato
AR074845A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
PE20180327A1 (es) Proceso para preparar 4-amino-piridazinas
MX2018001966A (es) Deshidrohalogenacion de hidroclorofluorocarburos.
AR090596A1 (es) Formulaciones farmaceuticas que comprenden antagonistas de ccr3
BR112015029714A2 (pt) processo para preparar derivados de 4,6-bis(ariloxi)pirimidina
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
AR080921A1 (es) Proceso para la preparacion de amidas de acido pirazolcarboxilico
MX394430B (es) Proceso para la preparación de 5-fluoro-1h-pirazoles.
AR109248A1 (es) Procedimiento para la preparación de 4-fenilbutirato y sus usos
AR093787A1 (es) Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos
MY182164A (en) Process for producing acetic acid by introducing a lithium compound
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
AR066054A1 (es) Proceso para preparar galantamina
MX383794B (es) Procedimiento para la preparacion de un derivado de furfural.
MX2021006065A (es) Procesos para la preparacion de propanedioles nitrosilados, composiciones que los comprenden y usos medicos de estos.
AR106195A1 (es) Proceso para la preparación de ácido 1-(4-metanosulfonil-2-trifluorometil-bencil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético e intermediarios de dicha síntesis
MX2018004338A (es) Proceso para sintesis de pirfenidona.
AR089376A1 (es) Proceso para la preparacion de oxido estanico